Researchers from Finland have developed a new tool for the objective diagnosis of Alzheimer’s disease which could allow for earlier diagnosis.
There may soon be an alternative to FDG-PET in the diagnosis of Alzheimer’s disease (AD) as the non-invasive arterial spin labeling (ASL) MRI method has been shown to provide comparable information, according to a study appearing in Neurology.
A new supplement to the Journal of Alzheimer’s Disease, “Imaging the Alzheimer Brain,” contains 31 papers that discuss the advances in imaging methodologies that are being used to understand, diagnose and treat Alzheimer’s disease.
Family history of Alzheimer disease (AD) is associated with several age-related changes that appear to influence AD biomarker abnormalities beyond the increased risk of the APOE4 gene, according to a report published in the October issue of Archives of Neurology. Previously, researchers suspected that AD has a lengthy preclinical period prior to the development of symptoms, in which cerebral lesions accumulate.
18F-FDG PET may provide a quantitative measure to detect progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD), and could offer a mechanism to streamline clinical trials, according to a study published in this month's Journal of Nuclear Medicine.
PET imaging is showing a 7 percent average annual growth rate from 2008 to 2010, which is a decrease from the average annual rate of 10.4 percent from 2005 to 2008, according to IMV's research report, 2011 PET Market Summary Report.
Individuals with deterministic genes in whom it is known that Alzheimer’s disease (AD) will develop appear to show differences in beta-amyloid distribution when compared with non-dominantly inherited AD patients, helping to consolidate evidence that PET and MRI can depict brain changes well before the arrival of AD-related symptoms, according to preliminary findings presented July 20 at the 2011 Alzheimer’s Association International Conference in Paris.
Researchers continue to make headway in grasping the biological nature of Alzheimer’s disease, with a recent study discovering significant increases in the beta-amyloid uptake of florbetapir F18 as viewed on PET, published July 11 in the Archives of Neurology.
Dynamic 11C-PiB PET can be used to measure cerebral beta-amyloid deposition in Down syndrome, according to a study published online March 14 in the Archives of Neurology.
|
|
|
|
RSS 
